One American Center,
Thousand Oaks,
California 91320
United States,
(805) 447-1000
www.amgen.com
Amgen Inc. is a drug development company focused on discovering, developing, manufacturing and delivering human therapeutics. Amgen uses tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and people's lives. Amgen Inc. was established in 1980 and is based in Thousand Oaks, California.
| Year | ≤ '13 | '14 | '15 | '16 | '17 | '18 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (0.2/yr) | # | 14 | - | 1 | - | - | - | 15 |
| vol | $34.9B | $34.9B | ||||||
| Sell (0.0/yr) | # | - | - | - | - | - | - | 0 |
| 15 | ||||||||
| Financial | Deals |
|---|---|
|
Sign-up to View
|
1 |
|
Sign-up to View
|
1 |
|
Sign-up to View
|
1 |
| Legal | Deals |
|---|---|
|
Sign-up to View
|
3 |
|
Sign-up to View
|
1 |
| Buy | # | TOTAL |
|---|---|---|
| > $1B | Sign-up to View | |
| $100M to $1B | Sign-up to View | |
| < $100M | Sign-up to View | |
| TOTAL | Sign-up to View | |
| Largest |
Immunex Corp. $16.0B (2002-07-16) |
|
| Sell | # | Total |
|---|---|---|
| > $1B | Sign-up to View | |
| $100M to $1B | Sign-up to View | |
| < $100M | Sign-up to View | |
| Total | Sign-up to View | |
According to our data here at Mergr, Amgen has acquired 15 companies, including 1 in the last 5 years. A total of 3 acquisitions came from private equity firms.
Amgen’s largest acquisition to date was in 2002, when it acquired Immunex for $16.0B. Amgen has acquired in 4 different US states, and 5 countries. The Company’s most targeted sectors include life science (94%) and medical products (7%).
When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 405 life science companies that have made at least 1 acquisition, 14 have acquired at least 5 companies, and 2 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 30 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 6 platform acquisitions.
Join Mergr and gain access to Amgen’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.
No obligation. Cancel anytime.
